Assenagon Asset Management
MYGN icon

Assenagon Asset Management’s Myriad Genetics MYGN Stock Holding History

Assenagon Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.89M Sell
1,031,464
-415,497
-29% -$1.89M 0.01% 627
2026
Q1 		$6.51M Buy
1,446,961
+279,227
+24% +$1.45M 0.01% 539
2025
Q4 		$7.18M Sell
1,167,734
-136,429
-10% -$989K 0.01% 578
2025
Q3 		$9.43M Buy
1,304,163
+979,133
+301% +$5.81M 0.01% 496
2025
Q2 		$1.73M Buy
325,030
+240,643
+285% +$1.42M ﹤0.01% 813
2025
Q1 		$749K Sell
84,387
-80,080
-49% -$962K ﹤0.01% 948
2024
Q4 		$2.25M Sell
164,467
-2,766
-2% -$51K ﹤0.01% 915
2024
Q3 		$4.58M Sell
167,233
-83,291
-33% -$2.25M 0.01% 741
2024
Q2 		$6.13M Buy
250,524
+52,813
+27% +$1.16M 0.01% 571
2024
Q1 		$4.22M Buy
197,711
+65,031
+49% +$1.4M 0.01% 644
2023
Q4 		$2.54M Sell
132,680
-143,541
-52% -$2.48M 0.01% 845
2023
Q3 		$4.43M Buy
276,221
+54,493
+25% +$1.04M 0.01% 612
2023
Q2 		$5.14M Buy
221,728
+110,743
+100% +$2.42M 0.02% 490
2023
Q1 		$2.58M Buy
110,985
+18,948
+21% +$385K 0.01% 749
2022
Q4 		$1.33M Buy
92,037
+79,652
+643% +$1.48M ﹤0.01% 962
2022
Q3 		$236K Sell
12,385
-31,750
-72% -$729K ﹤0.01% 1260
2022
Q2 		$802K Buy
44,135
+828
+2% +$17.2K ﹤0.01% 1130
2022
Q1 		$1.09M Buy
43,307
+12,064
+39% +$309K ﹤0.01% 1033
2021
Q4 		$862K Buy
+31,243
New +$905K ﹤0.01% 1077
2021
Q3 		– Sell
-18,036
Closed -$552K – 1387
2021
Q2 		$552K Buy
+18,036
New +$521K ﹤0.01% 1033
2020
Q4 		– Sell
-465,843
Closed -$6.08M – 1176
2020
Q3 		$6.08M Buy
+465,843
New +$5.9M 0.03% 289

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Assenagon Asset Management's MYGN Position: Q2 2026 in Review

Assenagon Asset Management reduced its Myriad Genetics (MYGN) stake by 29% in Q2 2026, selling an estimated $1.89M and leaving 1,031,464 shares worth $5.89M. The position accounts for 0.01% of the portfolio, ranked #627.

Assenagon Asset Management first reported a position in MYGN in Q3 2020 and has held it in 21 quarters since. The position peaked at $9.43M in Q3 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Assenagon Asset Management held 1,031,464 shares of Myriad Genetics worth $5.89M as of Q2 2026.
  • Assenagon Asset Management sold 415,497 Myriad Genetics shares in Q2 2026, an estimated $1.89M.
  • Myriad Genetics made up 0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #627 holding.
  • Assenagon Asset Management first reported a position in Myriad Genetics in Q3 2020 and has held it in 21 quarters since.
  • Assenagon Asset Management's Myriad Genetics position peaked at $9.43M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.